France· FR:61456335
URAPIDIL CRISTERS LP 30 mg, gélule à libération prolongée
A urapidil product containing urapidil, registered in France by CRISTERS, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Urapidil is registered in 10 of 19 countries.
Countries holding a registration under ATC C02CA06 (urapidil), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 6 of them publish a price we can compare per daily dose
Urapidil · ATC C02CA06
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Franceprice
- Germany
- Japan
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- URAPIDIL
- Manufacturer
- CRISTERS
- Country
- France (FR)
- ATC code
- C02CA06
- ATC class
- Urapidil
- Defined daily dose
- 0.12 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302028831 flacon(s) polyéthylène haute densité (PEHD) de 30 gélule(s)EUR 3.15
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Urapidil in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEBRANTIL RETARDCHEPLAPHARM Arzneimittel GmbH, Greifswald
- GermanyEbrantilCheplapharm Arzneimittel Gmbh
- PolandEbrantil 25CHEPLAPHARM Arzneimittel GmbH
- NetherlandsUrapidil ERC 50 mg oplossing voor injectie/infusieEuro Registratie Collectief B.V.
- SpainELGADIL 5 mg/ml SOLUCION INYECTABLE Y PARA PERFUSIONCheplapharm Arzneimittel Gmbh
- SwitzerlandEbrantil 50 mg, InjektionslösungCheplapharm Schweiz GmbH
- BelgiumEbrantil IV 25 5 mg/mlTakeda Belgium
- United KingdomUrapidil 60mg capsulesImported (Switzerland)
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Ebrantil, Galluper
- Belgium · Ebrantil I.V. 50
- Czechia · Ebrantil, Ebrantil Retard
- Germany · Ebrantil, Emersil I.V.
- Estonia · Urapidil Kalceks
- Spain · Urapidil Accord, Urapidil Kalceks
- Croatia · Ebrantil, Urapidil Kalceks
- Hungary · Ebrantil, Urapidil Kalceks
- Italy · Ebrantil, Urapidil Kalceks
- Luxembourg · Ebrantil I.V.
- Latvia · Urapidil Kalceks
- Netherlands · Urapidil Kalceks
- Poland · Ebrantil, Tachyben
- Portugal · Urapidil Kalceks, Urapidilo
- Romania · Tachyben, Urapidil Kalceks
- Slovenia · Ebrantil, Urapidil Kalceks
- Slovakia · Desurol, Ebrantil
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eb578b3a-6bd6-44c9-911b-856570ef0b2b GET /v1/drugs/eb578b3a-6bd6-44c9-911b-856570ef0b2b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61456335",
"date_amm": "2020-03-10",
"type_amm": "Procédure décentralisée",
"numero_ue": null,
"substance": "URAPIDIL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule à libération prolongée",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about urapidil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.